BaillieTA. Approaches to mitigate the risk of serious adverse reactions in covalent drug design. Expert Opin Drug Discov, 2021; 16(3):275–287; doi: 10.1080/17460441.2021.1832079.
2.
YangT, CuestaA, WanX, et al.Reversible lysine-targeted probes reveal residence time-based kinase selectivity. Nat Chem Biol, 2022 (In Press); doi: 10.1038/s41589-022-01019-1.
3.
SinghJ, PetterRC, BaillieTA, et al.The resurgence of covalent drugs. Nat Rev Drug Discov, 2011; 10(4):307–317; doi: 10.1038/nrd3410.
4.
SinghJ. The ascension of targeted covalent inhibitors. J Med Chem, 2022; 65(8):5886–5901; doi: 10.1021/acs.jmedchem.1c02134.
